PeptideInjectablePeptideSecretagogueGHRPGhrelin receptor agonist

Hexarelin

Also known as Hexarelin · Examorelin · EP-23905

Written by enwyReviewed 4 Aug 20262 sources0 comments

Hexarelin is a synthetic hexapeptide growth-hormone-releasing peptide (GHS-R agonist), more potent than GHRP-6 at releasing GH. It has been studied in small human trials for GH secretion and cardiovascular effects, but tachyphylaxis (desensitisation with continued use) and cortisol/prolactin stimulation limit it. Non-medical physique use is anecdotal.

01 Overview

Hexarelin strongly stimulates GH release and has independent cardioprotective actions at the CD36 and GHS receptors seen in preclinical and small clinical studies. It raises cortisol and prolactin somewhat, and GH response attenuates with sustained daily use as the receptor desensitises.

Because of desensitisation and the cortisol/prolactin effects it is used less than ipamorelin for ongoing body-composition goals. Human data exists for acute GH-releasing potency but not for physique endpoints.

02 Mechanism

Potent agonist of the growth-hormone secretagogue receptor (GHS-R1a) and CD36, evoking a strong GH pulse; also modestly raises ACTH/cortisol and prolactin, with receptor desensitisation on repeated dosing.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal (non-medical)	100–200 mcg	SubQ	~100-200 mcg per injection; response attenuates with continued daily use.

04 Effects

Effect	Magnitude	Evidence
Strong GH releasePotent acute GH-releasing effect demonstrated in small human studies; tolerance develops with repeated dosing.		Clinical
Fat loss and recoveryReported body-composition and recovery benefits; not established in controlled physique trials.		Anecdotal
Possible cardioprotective signallingGHS-R/CD36-mediated cardiac effects seen preclinically and in small studies; clinical relevance for users unproven.		Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence
Raised cortisol and prolactinHexarelin stimulates ACTH/cortisol and prolactin more than selective secretagogues.	Moderate	Common relative to selective GHRPs	Clinical
Tachyphylaxis (desensitisation)GH response falls with sustained daily dosing.	Mild	Very common with continued use	Clinical
Water retention / injection-site reactionsFluid retention and local injection reactions.	Mild	Common	Anecdotal

06 Legal status

United States

Research chemical; not FDA-approved for human use

WADA-prohibited; not lawfully marketed for human consumption. · as of Jan 2026

United Kingdom

Not licensed as a medicine

as of Jan 2026

07 References

Hexarelin: a potent GH-releasing peptide in humansJ Clin Endocrinol Metab, 1994

Cardiovascular actions of GH secretagogues / hexarelinPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.